First-in-human phase i study of PRS-050 (Angiocal), an anticalin targeting and antagonizing VEGF-A, in patients with advanced solid tumors

by Mross K., Richly H., Fischer R., Scharr D., Büchert M., Stern A., Gille H., Audoly L.P., Scheulen M.E.
Published 2019